Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts

Fibrogenesis and Tissue Repair

Volumn 4, Issue 1, 2011, Pages

  Krause, Carola ^a,b   Kloen, Peter ^c   Ten Dijke, Peter ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BONE MORPHOGENETIC PROTEIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG MECHANISM; DUPUYTREN CONTRACTURE; ENZYME PHOSPHORYLATION; EX VIVO STUDY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 79960953007     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-4-14     Document Type: Article

References (59)

1. Shaw RB, Chong AK, Zhang A, Hentz VR, Chang J. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007, 120:44e-54e. 10.1097/01.prs.0000278455.63546.03, 17700106.
2. Rayan GM. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007, 89:189-198.
3. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007, 170:1807-1816. 10.2353/ajpath.2007.070112, 1899462, 17525249.
4. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin 1999, 15:21-34.
5. Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction? Ultrastructural study. Am J Pathol 1972, 66:131-146. 2032479, 5009249.
6. Kloen P. New insights in the development of Dupuytren's contracture: a review. Br J Plast Surg 1999, 52:629-635. 10.1054/bjps.1999.3187, 10658134.
7. Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390:465-471. 10.1038/37284, 9393997.
8. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002, 62:65-74. 10.1124/mol.62.1.65, 12065756.
9. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003, 425:577-584. 10.1038/nature02006, 14534577.
10. Moustakas A, Heldin CH. Non-Smad TGF-β signals. J Cell Sci 2005, 118:3573-3584. 10.1242/jcs.02554, 16105881.
11. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007, 127:526-537. 10.1038/sj.jid.5700613, 17299435.
12. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363. 10.1038/nrm809, 11988769.
13. Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res 2000, 257:180-189. 10.1006/excr.2000.4869, 10854066.
14. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Transforming growth factor-β: possible roles in Dupuytren's contracture. J Hand Surg Am 1995, 20:101-108. 10.1016/S0363-5023(05)80067-X, 7722248.
15. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor β in Dupuytren's disease. J Hand Surg Am 1996, 21:210-215. 10.1016/S0363-5023(96)80102-X, 8683048.
16. Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 1993, 46:425-428. 10.1136/jcp.46.5.425, 501251, 8320323.
17. Zamora RL, Heights R, Kraemer BA, Erlich HP, Groner JP. Presence of growth factors in palmar and plantar fibromatoses. J Hand Surg Am 1994, 19:435-441. 10.1016/0363-5023(94)90058-2, 7520050.
18. Berndt A, Kosmehl H, Mandel U, Gabler U, Luo X, Celeda D, Zardi L, Katenkamp D. TGFβ and bFGF synthesis and localization in Dupuytren's disease (nodular palmar fibromatosis) relative to cellular activity, myofibroblast phenotype and oncofetal variants of fibronectin. Histochem J 1995, 27:1014-1020.
19. Wong M, Mudera V. Feedback inhibition of high TGF-β1 concentrations on myofibroblast induction and contraction by Dupuytren's fibroblasts. J Hand Surg Br 2006, 31:473-483. 10.1016/j.jhsb.2006.05.007, 16875762.
20. Bisson MA, Beckett KS, McGrouther DA, Grobbelaar AO, Mudera V. Transforming growth factor-β1 stimulation enhances Dupuytren's fibroblast contraction in response to uniaxial mechanical load within a 3-dimensional collagen gel. J Hand Surg Am 2009, 34:1102-1110. 10.1016/j.jhsa.2009.02.008, 19505772.
21. Tse R, Howard J, Wu Y, Gan BS. Enhanced Dupuytren's disease fibroblast populated collagen lattice contraction is independent of endogenous active TGF-β2. BMC Musculoskelet Disord 2004, 5:41. 10.1186/1471-2474-5-41, 534110, 15541177.
22. Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO. The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of α-smooth muscle actin and the response, to stimulation by TGF-β1. J Hand Surg Br 2003, 28:351-356. 10.1016/S0266-7681(03)00135-9, 12849947.
23. Bisson MA, Mudera V, McGrouther A, Grobbelaar AO. The contractile properties and responses to tensional loading of Dupuytren's disease-derived fibroblasts are altered: a cause of the contracture?. Plast Reconstr Surg 2004, 113:611-621. 10.1097/01.PRS.0000101527.76293.F1, 14758224.
24. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008, 28:1065-1079. 10.1111/j.1478-3231.2008.01826.x, 18783549.
25. Leask A, Parapuram SK, Shi-Wen X, Abraham DJ. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?. J Cell Commun Signal 2009, 3:89-94. 10.1007/s12079-009-0037-7, 2721078,2721078, 19156539.
26. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope D, Ross R. TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990, 63:515-524. 10.1016/0092-8674(90)90448-N, 2171777.
27. Shin SS, Liu C, Chang EY, Carlson CS, Di Cesare PE. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts. J Hand Surg Am 2004, 29:809-814. 10.1016/j.jhsa.2004.02.008, 15465229.
28. Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as antagonist of organ fibrosis. Front Biosci 2009, 14:4992-5012. 10.2741/3583, 19482601.
29. Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int 2008, 73:705-715. 10.1038/sj.ki.5002717, 18075500.
30. Grinell F, Ho CH. Transforming growth factor β stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp Cell Res 2002, 273:248-255. 10.1006/excr.2001.5445, 11822880.
31. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, Chaponnier C. α-smooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 2001, 12:2730-2741. 59708, 11553712.
32. Rayan GM, Tomasek JJ. Generation of contractile force by cultured Dupuytren's disease and normal palmar fibroblasts. Tissue Cell 1994, 26:747-756. 10.1016/0040-8166(94)90057-4, 9437248.
33. Augoff K, Kula J, Gosk J, Rutowski R. Epidermal growth factor in Dupuytren's disease. Plast Reconstr Surg 2005, 115:128-133.
34. Baird KS, Crossan JF, Ralston SH. Abnormal growth factor and cytokine expression in Dupuytren's contracture. J Clin Pathol 1993, 46:425-428. 10.1136/jcp.46.5.425, 501251, 8320323.
35. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494. 10.1074/jbc.270.46.27489, 7499206.
36. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
37. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, Killion JJ, Fidler IJ. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001, 7:2563-2572.
38. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000, 156:697-707. 10.1016/S0002-9440(10)64773-6, 1850054, 10666398.
39. Dandré F, Owens GK. Platelet-derived growth factor-BB and Ets-1 transcription factor negatively regulate transcription of multiple smooth muscle cell differentiation marker genes. Am J Physiol Heart Circ Physiol 2004, 286:H2042-2051. 10.1152/ajpheart.00625.2003, 14751865.
40. Masszi A, Speight P, Charbonney E, Lodyga M, Nakano H, Szászi K, Kapus A. Fate-determining mechanisms in epithelial-myofibroblast transition: major inhibitory role for Smad3. J Cell Biol 2010, 188:383-399. 10.1083/jcb.200906155, 2819691, 20123992.
41. Vindevoghel L, Lechleider RJ, Kon A, de Caestecker MP, Uitto J, Roberts AB, Mauviel A. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor β. Proc Natl Acad Sci USA 1998, 95:14769-1474. 10.1073/pnas.95.25.14769, 24524, 9843964.
42. Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P. The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. Cancer Res 2006, 66:2202-2209. 10.1158/0008-5472.CAN-05-3560, 16489022.
43. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, Karlsson S, ten Dijke P. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling. Mol Cell 2003, 12:817-828. 10.1016/S1097-2765(03)00386-1, 14580334.
44. Daly AC, Randall RA, Hill CS. Transforming growth factor β-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Mol Cell Biol 2008, 28:6889-6902. 10.1128/MCB.01192-08, 2573298, 18794361.
45. Nguyen TQ, Chon H, van Nieuwenhoven FA, Braam B, Verhaar MC, Goldschmeding R. Myofibroblast progenitor cells are increased in number in patients with type 1 diabetes and express less bone morphogenetic protein 6: a novel clue to adverse tissue remodelling?. Diabetologia 2006, 49:1039-1048. 10.1007/s00125-006-0172-0, 16547600.
46. Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 1984, 66:322-325.
47. Perron JC, Dodd J. ActRIIA and BMPRII type II BMP receptor subunits selectively required for Smad4-independent BMP7-evoked chemotaxis. PLoS One 2009, 4:e8198. 10.1371/journal.pone.0008198, 2788225, 20011660.
48. Song K, Krause C, Shi S, Patterson M, Suto R, Grgurevic L, Vukicevic S, van Dinther M, Falb D, ten Dijke P, Alaoui-Ismaili MH. Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity. J Biol Chem 2010, 285:12169-12180. 10.1074/jbc.M109.087197, 2852956, 20048150.
49. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: implications for carcinogenesis. Oncogene 2005, 24:5742-5750. 10.1038/sj.onc.1208928, 16123807.
50. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A. CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002, 62:1149-1159. 10.1111/j.1523-1755.2002.kid567.x, 12234285.
51. Leask A, Holmes A, Black CM, Abraham DJ. Connective tissue growth factor gene regulation: requirements for its induction by transforming growth factor-β2 in fibroblasts. J Biol Chem 2003, 278:13008-13015. 10.1074/jbc.M210366200, 12571253.
52. Guo B, Inoki K, Isono M, Mori H, Kanasaki K, Sugimoto T, Akiba S, Sato T, Yang B, Kikkawa R, Kashiwagi A, Haneda M, Koya D. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-β in rat mesangial cells. Kidney Int 2005, 68:972-984. 10.1111/j.1523-1755.2005.00491.x, 16105028.
53. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002, 16:1949-1951.
54. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, Feghali-Bostwick C, Varga J. Smad-independent transforming growth factor-β regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008, 173:1085-1099. 10.2353/ajpath.2008.080382, 2543076, 18772333.
55. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFβ, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010, 106:1675-1680. 10.1161/CIRCRESAHA.110.217737, 20538689.
56. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford) 2008, 47(Suppl 5):v2-v4.
57. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev 2004, 15:255-273. 10.1016/j.cytogfr.2004.03.006, 15207816.
58. Levitzki A. PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. Cytokine Growth Factor Rev 2004, 15:229-235. 10.1016/j.cytogfr.2004.03.010, 15207814.
59. Distler JH, Distler O. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies. Ann Rheum Dis 2010, 69(Suppl 1):i48-i51. 10.1136/ard.2009.120196, 19995744.